NCT05869591View on ClinicalTrials.gov

DOAC in Patients with Child a or B Liver Cirrhosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Liver Cirrhosis
Interventions
DRUG

Apixaban 5 MG [Eliquis]

Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child A or B liver cirrhosis

DRUG

Edoxaban 60 MG [Lixiana]

Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child A or B liver cirrhosis

Trial Locations (1)

1011

RECRUITING

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER